enGene Therapeutics Inc. Common Stock
$1.91
$0.00 (+0.00%)
$1.89Day Range$1.93
Key Statistics
Market Cap
$128.00M
Shares Outstanding
67.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 1, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$1.92
Day High
$1.93
Day Low
$1.89
Volume
401.0K
VWAP
$1.90
Prev Close
$1.91
Transactions
--
Acc. Volume
--
About enGene Therapeutics Inc. Common Stock
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283682 employees4868 RUE LEVY, SUITE 220, SAINT-LAURENT(514) 332-4888IPO Nov 1, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001980845
- Composite FIGI
- BBG01J1GCYW7
- Share Class FIGI
- BBG01J1GCYX6
- Ticker Root
- ENGN
- SIC Code
- 2836
About enGene Therapeutics Inc. Common Stock (ENGN) Stock
enGene Therapeutics Inc. Common Stock (ENGN) closed the 2026-09-18 session at $1.91, up 0.00% versus the previous close (+0.00). The stock opened at $1.92 and traded between $1.89 and $1.93 during that session. Session trading volume was 401K shares. The volume-weighted average price (VWAP) is $1.90.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
enGene Therapeutics Inc. Common Stock has a market capitalization of $128.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ENGN is listed on the XNAS exchange. The company employs approximately 82 people. The recorded listing date is 2023-11-01.
On this page you can find market ENGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.